This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Gilead, HiFiBiO Collaborate to Develop T-Cell Receptors
by Zacks Equity Research
To boost its pipeline, Gilead (GILD) collaborates with HiFiBiO Therapeutics for the development of T-cell receptors.
Roche Gets FDA Approval for New Formulation of Asthma Drug
by Zacks Equity Research
Roche (RHHBY) receives FDA approval for a dose prefilled syringe (PFS) formulation of its asthma drug, Xolair.
Pharma Stock Roundup: PFE, LLY Get Approval for New Drugs, Novartis to Cut Jobs
by Zacks Equity Research
FDA grants approval to Lilly's (LLY) Emgality for migraine and Pfizer's (PFE) Vizimpro for an advanced lung cancer indication. Novartis (NVS) to cut more than 2,000 jobs in Switzerland and U.K
Big Pharma Players on Strong Footing Ahead of Q4: 4 Picks
by Kinjel Shah
The large-cap pharma industry has been on a strong footing lately and looks well poised for Q4. Here are four stocks from the space that investors may consider betting on.
Glaxo's Tuberculosis Vaccine Positive in Mid-Stage Study
by Zacks Equity Research
Glaxo's (GSK) vaccine candidate, M72/AS01E, achieves significant reduction in incidence of pulmonary tuberculosis in HIV-negative patients with latent tuberculosis infection.
Theravance Up as CHMP Backs Trelegy Elipta Line Extension
by Zacks Equity Research
Theravance Biopharma (TBPH) highlights positive CHMP opinion supporting label expansion of Glaxo's COPD drug, Trelegy Elipta. Theravance has economic interest in the drug and earns royalties on its sales.
Gilead (GILD) to Launch Generics for Leading HCV Treatments
by Zacks Equity Research
Given the persistent decline in HCV sales, Gilead (GILD) plans to launch authorized generic versions of its leading hepatitis C virus (HCV) treatments, Epclusa and Harvoni.
Is GlaxoSmithKline plc (GSK) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (GSK) Outperforming Other Medical Stocks This Year?
Novartis Gets Positive CHMP Opinion for Drugs, Biosimilar
by Zacks Equity Research
Novartis (NVS) gets positive CHMP opinion for a label expansion of Gilenya, gene therapy, and a biosimilar of Neulasta.
Top Research Reports for Wells Fargo, Schlumberger & Biogen
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Wells Fargo (WFC), Schlumberger (SLB) and Biogen (BIIB).
AstraZeneca's Fasenra Long-Term Asthma Study Data Positive
by Zacks Equity Research
AstraZeneca's (AZN) asthma drug, Fasenra, maintains improvements achieved over first year of treatment in severe eosinophilic asthma patients for the next 56 weeks.
Should Value Investors Consider Glaxo (GSK) Stock Now?
by Zacks Equity Research
Let's see if GlaxoSmithKline plc (GSK) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Theravance, Mylan Report Positive Data on COPD Drug Yupelri
by Zacks Equity Research
Theravance (TBPH) and partner Mylan post positive data from a late-stage program on COPD Drug, Yupelri.
Glaxo Seeks EU Approval for Two-Drug Regimen in First-Line HIV
by Zacks Equity Research
Glaxo (GSK) submits a regulatory application in the EU for a single-tablet, two-drug regimen of dolutegravir and lamivudine for the first-line treatment of HIV-1 infection.
Is Artificial Intelligence the Next Big Thing in Biotech?
by Kinjel Shah
Artificial intelligence can drastically reduce the time taken to develop new life-saving drugs.
Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus
by Zacks Equity Research
Label expansion of Merck's (MRK) Keytruda and FDA approval of AstraZeneca's (AZN) leukemia drug grab headlines this week
Merck Gets Priority Review for Yet Another Keytruda sBLA
by Zacks Equity Research
Merck's (MRK) sBLA to include overall survival data from a key lung cancer study on Keytruda's label gets FDA's priority review. If approved, it will expand the eligible patient population.
Gilead's Rheumatoid Arthritis Drug Successful in Phase III
by Zacks Equity Research
Gilead (GILD) and partner Galapagos' rheumatoid arthritis candidate meets all primary and key secondary endpoints in first phase III study.
Glaxo's Nucala Suffers Regulatory Setback, Gets CRL for COPD
by Zacks Equity Research
FDA issues a complete response letter to Glaxo's (GSK) application for label expansion of its asthma drug, Nucala for COPD.
Gilead, Galapagos Spondylitis Drug Meets Primary Endpoint
by Zacks Equity Research
Gilead's (GILD) ankylosing spondylitis candidate, filgotinib meets primary endpoint in phase II study.
Novartis to Sell Sandoz's Dermatology Business to Aurobindo
by Zacks Equity Research
Novartis (NVS) looks to sell Sandoz's dermatology business in the United States and generic U.S. oral solids portfolio, to Aurobindo Pharma USA Inc., for $0.9 billion.
Merck's Keytruda Gets Priority Review for Rare Skin Cancer
by Zacks Equity Research
Merck's (MRK) sBLA for Keytruda to expand its label for a rare form of skin cancer gets priority review from FDA.
Mylan Suffers Several Setbacks: What's in Store in 2H18?
by Zacks Equity Research
Mounting competition and recent setbacks cast a pall over Mylan's (MYL) near-term performance.
AstraZeneca's Lupus Drug Misses Primary Endpoint in Study
by Zacks Equity Research
AstraZeneca's (AZN) phase III study, evaluating anifrolumab in adult patients with moderate-to-severe systemic lupus erythematosus, does not meet primary endpoint.
Merck (MRK) Receives FDA Approval for Two HIV Medicines
by Zacks Equity Research
Merck's (MRK) two new HIV-1 medicines, Delstrigo and Pifeltro, get approval in the United States.